26 November 2021: Articles
A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
Unusual or unexpected effect of treatment
Anupamjeet Kaur Sekhon B* , Aniruddha Gollapalli E , Dharamjeet Kaur E , Bryan Janssen D , Mark L. Stevens E , Fernando Valerio A , Miguel A. Sierra-Hoffman EDOI: 10.12659/AJCR.932961
Am J Case Rep 2021; 22:e932961
Table 3. Laboratory studies before first liver biopsy.
| Test | Result | Reference range |
|---|---|---|
| Ferritin | 72 ng/mL | 13–200 ng/mL |
| Ceruloplasmin | 42.9 mg/dL | 16–45 mg/dL |
| LKM antibody | 1.2 U | |
| Alpha-1-antitrypsin | 212 mg/dL | 90–200 mg/dL |
| Smooth muscle AB (F-Actin) | 8.0 U | |
| Soluble liver AG AB | 1.6 U | 0–24.9 U |
| GGT | 212 U/L | < 40 U/L |
| AFP marker | 1.6 ng/mL | |
| Hepatitis A total Ab | Reactive | Non-reactive |
| Hepatitis A IgM | Non-reactive | Non-reactive |
| Hep B core total Ab | Non-reactive | Non-reactive |
| Hepatitis B surface Ag | Non-reactive | Non-reactive |
| Hepatitis B surface Ab | Reactive | Non-reactive |
| Hepatitis Bs AB Quant | 25.30 MIU/mL | >11.50 MIU/mL |
| Hepatitis C antibody | Non-reactive | Non-reactive |
| Hepatitis C antibody | 0.11 | |
| Mitochondrial M2 AB | 1.9 U | |
| TTG IgG | ||
| TTG IgA | ||
| Anti-nuclear antibodies | Negative | Negative |
| Sjogren’s SS-A antibody | ||
| Sjogren’s SS-B antibody | ||
| Smith (Sm) antibody | ||
| RNP antibody | ||
| SCL-70 antibody | ||
| Jo-1 antibody | ||
| Centromere B antibody | ||
| Ribosomal P antibody | ||
| Chromatin antibody | ||
| Thyroid peroxidase antibody | ||
| Rheumatoid Factor, Quant | ||
| Complement C3 | 145 mg/dL | 90–180 mg/dL |
| Complement C4 | 22 mg/dL | 10–40 mg/dL |
| dsDNA antibody | ||
| TSH | 2.370 UIU/mL | 0.4–4.1 UIU/mL |
| T4 (thyroxine) | 7.3 UG/dL | 4.5–10.5 UG/dL |
| Corrected T4 (FTI) | 6.6 UG/dL | 4.2–11.6 UG/dL |
| T-uptake | 30.2% | 24.3–39.0% |
| Thyroxine binding capacity | 1.1 | 0.8–1.3 |